LeonaBio, Inc. Common Stock LONA Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Excluding Stockbased Or Depreciation Expense by Product | ||||||
| ATH-1105 | $2.73M-67.5% | $3.42M-60.1% | $4.61M— | $6.37M— | $8.42M— | |
| Fosgonimeton ATH-1017 | $1.21M-95.8% | $2.33M-94.4% | $6.09M-88.8% | $15.85M-73.9% | $28.55M-55.5% | |
| Personnel-Related Costs Excluding Stock-Based Compensation | $4.72M-51.2% | $4.22M-65.6% | $5.13M-61.8% | $7.42M-46.1% | $9.66M-31.4% | |
| Preclinical Programs And Other Costs | $1.2M-55.1% | $1.25M-72.0% | $1.39M-77.0% | $1.99M-72.5% | $2.68M-67.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LeonaBio, Inc. Common Stock break its business down?
- LeonaBio, Inc. Common Stock (LONA) reports research and development expense excluding stockbased or depreciation expense by product across 8 parts — Acquired In Process Research And Development, ATH-1020, ATH-1105, Fosgonimeton ATH-1017 and Lasofoxifene. Each is extracted from the segment footnotes and tracked over time.
- Where does LeonaBio, Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LeonaBio, Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.